Tumor erlotinib and sunitinib concentrations were consistent with small sample-sized studies suggesting 4–20× higher concentrations of (mostly EGFR) tyrosine kinase inhibitors in tumor than in plasma [27,28,29]. Here, EGFR is linked to neoplasm.